Westwood Holdings Group Inc. Makes New $1.40 Million Investment in Cabaletta Bio, Inc. (NASDAQ:CABA)

Westwood Holdings Group Inc. bought a new position in Cabaletta Bio, Inc. (NASDAQ:CABA) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 82,228 shares of the company’s stock, valued at approximately $1,403,000. Westwood Holdings Group Inc. owned approximately 0.18% of Cabaletta Bio as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Macroview Investment Management LLC purchased a new stake in Cabaletta Bio in the fourth quarter worth about $26,000. Tower Research Capital LLC TRC grew its stake in shares of Cabaletta Bio by 65.9% in the 4th quarter. Tower Research Capital LLC TRC now owns 2,623 shares of the company’s stock worth $60,000 after buying an additional 1,042 shares during the last quarter. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Cabaletta Bio in the 4th quarter worth approximately $113,000. EntryPoint Capital LLC bought a new position in Cabaletta Bio during the 1st quarter valued at approximately $147,000. Finally, SG Americas Securities LLC purchased a new position in Cabaletta Bio during the fourth quarter valued at $221,000.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on CABA shares. HC Wainwright reissued a “buy” rating and issued a $30.00 target price on shares of Cabaletta Bio in a research note on Friday, June 14th. Stifel Nicolaus restated a “buy” rating and set a $32.00 price objective on shares of Cabaletta Bio in a research note on Monday, June 17th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $50.00 target price on shares of Cabaletta Bio in a report on Friday, June 21st. Finally, Citigroup increased their price target on shares of Cabaletta Bio from $26.00 to $30.00 and gave the company a “buy” rating in a report on Thursday, April 4th. Nine analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Cabaletta Bio has a consensus rating of “Buy” and an average price target of $34.44.

Cabaletta Bio Stock Performance

Shares of CABA traded up $0.44 during mid-day trading on Friday, hitting $7.19. 591,227 shares of the company traded hands, compared to its average volume of 966,798. The stock has a market cap of $347.13 million, a price-to-earnings ratio of -4.20 and a beta of 2.42. The stock has a 50-day moving average price of $9.02 and a two-hundred day moving average price of $15.27. Cabaletta Bio, Inc. has a 1 year low of $6.71 and a 1 year high of $26.35.

Cabaletta Bio (NASDAQ:CABA) last posted its earnings results on Wednesday, May 15th. The company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.03). On average, analysts forecast that Cabaletta Bio, Inc. will post -2.07 EPS for the current year.

Cabaletta Bio Company Profile

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.